Legend Biotech disclosed early clinical data from an investigator-initiated trial of its in vivo CAR-T therapy in lymphoma, reporting results across 12 patients. The company said the treatment reduced or eliminated signs of disease in all recipients, signaling potential momentum for a modality that delivers CAR components in the body rather than manufacturing ex vivo cells. The first data point arrives as in vivo CAR-T strategies continue to compete with established ex vivo approaches, including the broader “T-cell redirecting” pipeline where speed, scalability, and durability remain key differentiators.